Clinical trials: sponsored by AbbVie
HCV Infection
Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects
The purpose of this study is to assess the safety, tolerability, pharmacokinetics of ABT-333 in healthy volunteers and the antiviral activity in HCV infected subjects.
- Trial name
- NCT00696904
- Testing
- ABT-333
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- AbbVie
Advanced Solid Tumors
Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869
To estimate the effect of food on the oral bioavailability and effect of diurnal variation on the pharmacokinetics of ABT-869.
- Trial name
- NCT00733187
- Testing
- ABT-869
- Volunteers
- 34 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Glioblastoma Multiforme
Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme
This study is evaluating the safety and pharmacokinetics of ABT-414 in subjects with glioblastoma multiforme.
- Trial name
- NCT01800695
- Testing
- ABT-414, Temozolomide, Whole Brain Radiation
- Volunteers
- 202 people
- Sponsor
- AbbVie
Lymphoma, Including Chronic Lymphocytic Leukemia, Solid Tumors
A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax
This is an open-label, single or multiple center study to determine the interaction of rifampin with navitoclax (ABT-263) in approximately 12 subjects with cancer.
- Trial name
- NCT01121133
- Testing
- navitoclax, Rifampin
- Volunteers
- 12 people
- Sponsor
- AbbVie
Major Depressive Disorder
Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder
This is a multiple-dose study to assess the safety and pharmacology of ABT-436 in physically healthy subjects with mild to moderate depressive symptoms who are not taking any antidepressant medication.
- Trial name
- NCT01380704
- Testing
- ABT-436
- Volunteers
- 51 people
- Sponsor
- AbbVie
Solid Tumor
A Phase 1 Study of ABT-869 in Subjects With Solid Tumors
The objective of this study is to evaluate the pharmacokinetics, safety and tolerability of ABT-869 in Japanese patients with solid tumors up to the Recommended Phase Two Dose that was determined in a previous the M04-710 study.
- Trial name
- NCT00718380
- Testing
- ABT-869
- Volunteers
- 18 people
- Sponsor
- AbbVie
Non-hematologic Malignancies, Metastatic Melanoma
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Temozolomide (chemotherapy) in treating patients with solid tumors, including metastatic melanoma (MM), BRCA deficient…
- Conditions
- Non-hematologic Malignancies, Metastatic Melanoma, Breast Cancer, Ovarian Cancer
- Trial name
- NCT00526617
- Testing
- ABT-888, Temozolomide
- Volunteers
- 41 people
- Sponsor
- AbbVie
Lymphoid Malignancy, Solid Tumors
Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer
This is a randomized, single dose, open-label, multicenter crossover study to determine the oral bioavailability of a new ABT-263 formulation relative to that of the current ABT-263 formulation being administered in ongoing Phase…
- Trial name
- NCT00982566
- Testing
- ABT-263
- Volunteers
- 37 people
- Sponsor
- AbbVie
Non-small Cell Lung Cancer
A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC)
The primary purpose of this study is to examine the safety of volociximab in combination with a standard treatment of carboplatin and paclitaxel in subjects previously untreated with chemotherapy for advanced stage (IIIB/IV)…
- Trial name
- NCT00654758
- Testing
- M200 (Volociximab), Carboplatin, Paclitaxel
- Volunteers
- 33 people
- Sponsor
- AbbVie
Brain Diseases, Brain Neoplasms
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Whole Brain Radiation Therapy (WBRT) in treating patients with brain metastases.
- Conditions
- Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, Neoplasm Metastasis
- Trial name
- NCT00649207
- Testing
- ABT-888, Whole Brain Radiation Therapy
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 80 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Parkinson Disease
A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease
A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects with Advanced Parkinson's Disease.
- Trial name
- NCT01484990
- Testing
- Levodopa-Carbidopa
- Volunteers
- 19 people
- Sponsor
- AbbVie
Advanced Solid Tumors
A Study of ABT-806 in Subjects With Advanced Solid Tumor Types
This is an open-label study designed to determine the recommended Phase 2 dose (RPTD) and evaluate the safety and pharmacokinetics of ABT-806 in subjects with advanced solid tumors.
- Trial name
- NCT01255657
- Testing
- ABT-806
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Solid Tumors
Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors
This is a Phase 1 open-label study evaluating the safety of navitoclax (ABT-263) when combined with a standard regimen of gemcitabine in approximately 50 subjects with solid tumors and measurable disease.
- Trial name
- NCT00887757
- Testing
- ABT-263, gemcitabine
- Volunteers
- 46 people
- Sponsor
- AbbVie
Advanced Solid Tumors
Study of ABT-700 in Subjects With Advanced Solid Tumors
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-700 in subjects with advanced solid tumors that may have MET amplification or c-Met overexpression.
- Trial name
- NCT01472016
- Testing
- ABT-700, docetaxel, FOLFIRI
- Volunteers
- 74 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Solid Tumors
To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors
Compare the bioavailability of three veliparib formulations in subjects with solid tumors.
- Trial name
- NCT01199224
- Testing
- veliparib
- Volunteers
- 27 people
- Sponsor
- AbbVie
Solid Tumors
Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors
Safety study of ABT-263 in Combination with Paclitaxel in Subjects with Solid Tumors.
- Trial name
- NCT00891605
- Testing
- ABT-263, paclitaxel
- Volunteers
- 19 people
- Sponsor
- AbbVie
Prostate Cancer
A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer
Assess whether the combination of ABT-888 with temozolomide (TMZ) has activity in subjects with metastatic castration resistant prostate cancer (CRPC) as reflected by the prostate-specific antigen (PSA) response.
- Trial name
- NCT01085422
- Testing
- ABT-888, temozolomide
- Volunteers
- 35 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Asthma
Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma
The primary purpose of this study is to determine the safety, tolerability and pharmacokinetics of ABT-308 in healthy volunteers and patients with mild to moderate controlled asthma.
- Trial name
- NCT00986037
- Testing
- ABT-308
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- AbbVie
Non-Small Cell Lung Cancer
A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)
The primary objective of this study is to assess the safety and pharmacokinetics of linifanib, and identify tolerable dose of linifanib (ABT-869) in combination with carboplatin and paclitaxel in Japanese subjects with advanced…
- Trial name
- NCT01225302
- Testing
- Linifanib, Carboplatin, Paclitaxel
- Volunteers
- 12 people
- Sponsor
- AbbVie
Advanced Solid Tumors
An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors
An extension study of linifanib in subjects with advanced or metastatic solid tumors.
- Trial name
- NCT01413893
- Testing
- linifanib
- Volunteers
- 35 people
- Sponsor
- AbbVie